Salarius Pharmaceuticals (SLRX) Competitors $5.77 +0.45 (+8.46%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$5.63 -0.14 (-2.44%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock SLRX vs. GRI, NBY, VRAX, CERO, RDHL, QLGN, BIVI, ELAB, ENVB, and PWUPShould you be buying Salarius Pharmaceuticals stock or one of its competitors? The main competitors of Salarius Pharmaceuticals include GRI Bio (GRI), NovaBay Pharmaceuticals (NBY), Virax Biolabs Group (VRAX), CERo Therapeutics (CERO), Redhill Biopharma (RDHL), Qualigen Therapeutics (QLGN), BioVie (BIVI), PMGC (ELAB), Enveric Biosciences (ENVB), and PowerUp Acquisition (PWUP). These companies are all part of the "pharmaceutical products" industry. Salarius Pharmaceuticals vs. Its Competitors GRI Bio NovaBay Pharmaceuticals Virax Biolabs Group CERo Therapeutics Redhill Biopharma Qualigen Therapeutics BioVie PMGC Enveric Biosciences PowerUp Acquisition Salarius Pharmaceuticals (NASDAQ:SLRX) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, media sentiment, dividends, institutional ownership, analyst recommendations, profitability and earnings. Do analysts recommend SLRX or GRI? GRI Bio has a consensus target price of $22.00, suggesting a potential upside of 1,471.43%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than Salarius Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Salarius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SLRX or GRI more profitable? GRI Bio's return on equity of -327.62% beat Salarius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Salarius PharmaceuticalsN/A -556.47% -192.35% GRI Bio N/A -327.62%-191.40% Which has higher earnings and valuation, SLRX or GRI? Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSalarius PharmaceuticalsN/AN/A-$5.58M-$43.48-0.13GRI BioN/AN/A-$8.21M-$11.56-0.12 Does the media favor SLRX or GRI? In the previous week, Salarius Pharmaceuticals had 5 more articles in the media than GRI Bio. MarketBeat recorded 6 mentions for Salarius Pharmaceuticals and 1 mentions for GRI Bio. GRI Bio's average media sentiment score of 0.75 beat Salarius Pharmaceuticals' score of -0.20 indicating that GRI Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Salarius Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GRI Bio 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SLRX or GRI? Salarius Pharmaceuticals has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.61, meaning that its share price is 261% less volatile than the S&P 500. Do insiders & institutionals have more ownership in SLRX or GRI? 11.9% of Salarius Pharmaceuticals shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 1.2% of Salarius Pharmaceuticals shares are held by insiders. Comparatively, 0.9% of GRI Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryGRI Bio beats Salarius Pharmaceuticals on 9 of the 13 factors compared between the two stocks. Get Salarius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLRX vs. The Competition Export to ExcelMetricSalarius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.71M$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-0.1322.6131.1026.05Price / SalesN/A554.26433.22103.03Price / CashN/A180.4637.7358.48Price / Book-3.545.939.536.61Net Income-$5.58M$31.83M$3.26B$265.56M7 Day PerformanceN/A1.89%2.10%1.97%1 Month Performance-45.05%1.33%2.81%-0.36%1 Year Performance-79.32%8.84%30.56%19.03% Salarius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLRXSalarius Pharmaceuticals0.1311 of 5 stars$5.77+8.5%N/A-79.3%$2.71MN/A-0.1320Analyst UpgradeStock SplitGRIGRI Bio1.7604 of 5 stars$1.48+1.0%$22.00+1,382.1%-83.5%$3.74MN/A-0.131News CoverageShort Interest ↑NBYNovaBay Pharmaceuticals0.3869 of 5 stars$0.62-0.5%$0.85+37.1%+80.6%$3.61M$9.78M-0.0130VRAXVirax Biolabs Group3.2276 of 5 stars$0.780.0%$3.00+283.1%-85.2%$3.40M$10K0.005Short Interest ↓Gap UpCEROCERo Therapeutics3.4801 of 5 stars$8.74-0.7%$45.00+414.9%-97.1%$3.40MN/A0.008Earnings ReportRDHLRedhill BiopharmaN/A$1.44-0.3%N/A-86.3%$3.30M$8.04M0.00210Gap UpQLGNQualigen TherapeuticsN/A$1.94+2.1%N/A-82.3%$3.18M$4.98M0.0050Gap UpBIVIBioVie0.3616 of 5 stars$1.70-2.9%N/A-95.2%$3.16MN/A-0.0210Analyst DowngradeELABPMGC0.9159 of 5 stars$1.99+0.5%N/A-99.3%$2.95M$1.71M0.0018News CoverageENVBEnveric Biosciences1.4865 of 5 stars$1.16-2.5%$10.00+762.1%-84.7%$2.87MN/A-0.0320Positive NewsPWUPPowerUp AcquisitionN/A$0.36-7.8%N/AN/A$2.79MN/A0.00N/AHigh Trading Volume Related Companies and Tools Related Companies GRI Competitors NBY Competitors VRAX Competitors CERO Competitors RDHL Competitors QLGN Competitors BIVI Competitors ELAB Competitors ENVB Competitors PWUP Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLRX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access